Tyra Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$132.8M | -$104.2M | -$79.9M | -$58.9M | -$26.3M |
| Operating expenses | $132.8M | $104.2M | $79.9M | $58.9M | $26.3M |
| Cash from operations | -$95.1M | -$69.8M | -$50.1M | -$50.3M | -$23.7M |
| Capital expenditure | $141,000 | $664,000 | $770,000 | $559,000 | $661,000 |
| Free cash flow | -$95.3M | -$70.4M | -$50.9M | -$50.8M | -$24.4M |
| Total assets | $282.6M | $363.6M | $225.9M | $266.2M | $306.7M |
| Total liabilities | $23.4M | $20.4M | $21.6M | $8.4M | $5.0M |
Shares outstanding 59.5M · Free float 58.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.